AtriCure Inc
NASDAQ:ATRC

Watchlist Manager
AtriCure Inc Logo
AtriCure Inc
NASDAQ:ATRC
Watchlist
Price: 30.52 USD 0.07%
Market Cap: 1.5B USD
Have any thoughts about
AtriCure Inc?
Write Note

Net Margin
AtriCure Inc

-8.7%
Current
-2%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8.7%
=
Net Income
-38.9m
/
Revenue
447.6m

Net Margin Across Competitors

Country US
Market Cap 1.5B USD
Net Margin
-9%
Country US
Market Cap 199.5B USD
Net Margin
14%
Country US
Market Cap 190.6B USD
Net Margin
29%
Country US
Market Cap 140.3B USD
Net Margin
16%
Country US
Market Cap 133.7B USD
Net Margin
11%
Country IE
Market Cap 104.5B USD
Net Margin
13%
Country US
Market Cap 65.8B USD
Net Margin
9%
Country DE
Market Cap 58.1B EUR
Net Margin
8%
Country US
Market Cap 44.3B USD
Net Margin
74%
Country CN
Market Cap 308.3B CNY
Net Margin
33%
Country US
Market Cap 36.4B USD
Net Margin
9%
No Stocks Found

AtriCure Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Nestled in the heart of the highly competitive medical device industry, AtriCure Inc. has carved a significant niche for itself by focusing on the surgical treatment of atrial fibrillation, a common and potentially serious heart rhythm disorder. Founded in 2000 and headquartered in Mason, Ohio, AtriCure designs, manufactures, and sells an array of surgical devices aimed at improving treatment outcomes for this condition. The company’s innovative technology targets the complex network of electrical signals in the heart to restore regular rhythm and mitigate the risk of stroke—a common consequence of untreated atrial fibrillation. By providing surgeons with minimally invasive tools and advanced cryoablation and radiofrequency therapy systems, AtriCure not only addresses surgical efficiency but also enhances patient recovery times, distinguishing itself from its competitors. AtriCure derives its revenue from the sale of these sophisticated products directly to hospitals and surgical centers both in the United States and internationally. Key components of its portfolio include the Synergy Ablation System, which is acclaimed for its precision in creating lesions that block erratic electrical pathways, and AtriClip, a line of devices designed to occlude the left atrial appendage, thereby reducing stroke risk. As healthcare providers increasingly recognize the benefits of surgical intervention for atrial fibrillation over alternative treatments, AtriCure's financial health is buoyed by the rising adoption of its products. The company's strategic focus on expanding its product pipeline and enhancing its global sales footprint underscores its commitment to continuous growth and innovation in cardiac care.

ATRC Intrinsic Value
51 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8.7%
=
Net Income
-38.9m
/
Revenue
447.6m
What is the Net Margin of AtriCure Inc?

Based on AtriCure Inc's most recent financial statements, the company has Net Margin of -8.7%.